<DOC>
	<DOCNO>NCT00067548</DOCNO>
	<brief_summary>This non-randomized , open-label , outpatient clinical trial design assess safety efficacy daily orally administer EKB-569 subject advance non-small cell lung cancer . Patients must previously treat platinum- docetaxel-based therapy either give concurrently separate regimen . The primary objective study assess clinical activity EKB-569 administer orally second-line late stage treatment subject advance non-small cell lung cancer . Secondary objective include : - To evaluate safety EKB-569 - To explore additional clinical activity parameter - To explore subject survival - To evaluate pharmacokinetics EKB-569 - To assess subject report outcomes EKB-569 administer orally single-agent . Eligible subject take EKB-569 daily long progressive disease tolerate treatment .</brief_summary>
	<brief_title>Study Evaluating EKB-569 Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Signed dated , institutional review board ( IRB ) independent ethic committee ( IEC ) approve informed consent form protocolspecific screening procedure Histologic and/or cytologic diagnosis locallyadvanced metastatic nonsmall cell lung cancer subject curable conventional therapy Chemotherapy , radiotherapy , anticancer immunotherapy , investigational agent within 4 week treatment day 1 ( 6 week previous regimen include mitomycin nitrosoureas ) Prior radiotherapy &gt; 25 % bone marrow Prior epidermal growth factor receptortargeting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
</DOC>